Deinove appoints Dr. Alexis Rideau as CEO

– FRANCE, Montpellier –  Deinove (EPA: ALDEI), a biotech company pioneering the exploration and exploitation of bacterial biodiversity to address the urgent and global challenge of antimicrobial resistance, today announced the appointment of Dr. Alexis Rideau Ph.D. as CEO, effective on January 8, 2021.

“The Board of Directors and I confirm our full confidence in Alexis. Since his entry in the company, he has driven the momentum we were expecting from his appointment as Deputy CEO. In just a few months, he has strengthened the Company’s positioning in the antimicrobial field and worked to promote Deinove’s scientific capabilities to its current and future partners. He is now the CEO of this biotech company with high potential in the race against antimicrobial resistance”, said Board Chairman, Charles Woler.

About Dr. Alexis Rideau

Before joining DEINOVE, Alexis Rideau was in charge of developing industrial relations and coordinating the strategic partnership team at BIOASTER (Lyon/Paris), a Technology Research Institute in applied microbiology, which specializes in the design and use of technology innovations in the field of microbiology to accelerate the development of medical and nutritional industrial solutions for animal and human health.

Alexis Rideau has been directly involved in the definition and implementation of the Institute’s technology and economic strategy, as well as the valorization of its state-of-the-art technology platforms in the industrial sectors of microbiota, antimicrobials, vaccines, and diagnostic. He initiated and implemented structuring partnerships, technologically and financially, with major French and international players (Takeda Pharmaceuticals, Bio-Rad Laboratories, bioMérieux, Boehringer Ingelheim, etc.), SMEs (Kaleido Biosciences Inc., Enterome, MaaT Pharma, LNC Therapeutics, Biofilm Pharma, etc.) and academic institutions (INRAE MetaGenoPolis, Institut Pasteur, CNRS, etc.).

Previously, Alexis Rideau held various positions in companies operating in the technology and healthcare fields, including support to entrepreneurs, sector analysis and fundraising (Library House Ltd, Bionest Partners, and Glaizer Group) and directly in the field, in the conquest of new industrial markets (MorphoSys AG, Bio-Rad Laboratories).

“I would like to thank Charles Woler and all the members of the Board of Directors for renewing their confidence in me. Since last May, I have been working on the operating transformation to ensure that it becomes a leading driver of innovation in the exploration and exploitation of microbial biodiversity. The energy and determination of Deinove’s teams made it possible for me to take up my position under optimal conditions, despite the context of the COVID-19 pandemic. Together we are fully committed to developing Deinove as a major player in the generation of new antimicrobials”, commented Alexis Rideau, CEO of Deinove.

Alexis Rideau holds a Ph.D. in Molecular and Cellular Biology (University of Cambridge, England), a European Magistère in Genetics, and an MSc in Cellular and Molecular Genetics (Paris Diderot University and Sorbonne University), as well as an MBA in International Management (ESCP Europe).

About Deinove

Deinove is a French biotechnology company pioneering the exploration of a new domain of life, unexplored at 99.9%: the “microbial dark matter”. By revealing the metabolic potential of rare bacteria or still classified as uncultivable, it tackles a global health and economic challenge: antimicrobial resistance. The new therapies discovered and developed by Deinove target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.

This breakthrough approach gave birth to one of the World’s first specialized micro-biotechnology platforms and a unique collection of 10,000 rare strains and thousands of bacterial extracts. Nowadays, Deinove is conducting several development programs, of which its first antibiotic candidate is currently evaluated in Phase II clinical trial in severe Clostridioides difficult infections, one of the World’s primary emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.
Based at the heart of the Euromédecine park in Montpellier, Deinove is listed on EURONEXT GROWTH® since 2010. The Company has more than 50 employees and leans on a world-class network of academic, technological, industrial, and institutional partners.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team